We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for Myriad Genetics (MYGN - Free Report) . Shares have added about 4.1% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Myriad due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Myriad Genetics, Inc. reported fourth-quarter 2025 adjusted earnings of 4 cents per share, which surpassed the Zacks Consensus Estimate by 350% and increased 33.3% year over year.
Adjusted earnings exclude amortization expenses from acquired intangible assets, equity compensation and real estate optimization. GAAP loss per share came in at 8 cents in the quarter compared with the prior-year quarter’s loss of 47 cents.
For the full year, adjusted earnings were 6 cents per share compared with the year-ago period’s earnings of 14 cents. The Zacks Consensus Estimate projected the company’s 2025 earnings per share to be flat.
MYGN’s Revenues
Total revenues fell 0.4% year over year to $209.8 million but exceeded the Zacks Consensus Estimate by 1.07%. Testing volumes increased 2% year over year.
For full-year 2025, revenues totaled $824.5 million, declining 1.6% from the year-ago period. The figure topped the Zacks Consensus Estimate slightly by 0.3%.
Detailed Breakdown of MYGN’s Q4 Revenues
In the fourth quarter, Hereditary Cancer testing revenues increased 3% year over year to $96.8 million. Tumor Profiling testing revenues rose 2% year over year to $31.5 million. Prenatal testing revenues came in flat at $44.9 million, while Mental Health revenues decreased 10% to $36.6 million.
MYGN’s Q4 Margin Performance
The gross margin fell 168 basis points (bps) to 70% due to a 5.5% increase in the cost of revenues.
Research and development expenses dropped 14.1% year over year to $25.5 million. SG&A expenses dipped 16.4% to $55.6 million in the reported quarter.
The adjusted operating loss was $3 million compared with a loss of $17.3 million in the year-ago quarter.
MYGN’s Financial Position
Myriad Genetics exited the fourth quarter of 2025 with cash and cash equivalents of $149.6 million compared with $102.4 million at the end of the fourth quarter of 2024.
Long-term debt amounted to $119.9 million, higher than $39.6 million at the end of the fourth quarter of 2024.
The cumulative net cash outflow from operating activities at the end of the reported quarter was $1.8 million compared with an outflow of $8.7 million in the year-ago period.
Myriad Genetics’ 2026 Guidance
Myriad Genetics reiterated its full-year 2026 guidance, which it introduced during preliminary fourth-quarter 2025 results in January. Revenues are expected to be between $860 million and $880 million in 2026. The Zacks Consensus Estimate is pegged at $867.5 million.
Full-year adjusted gross margin is expected to be in the 68%-69% range. Adjusted EBITDA is forecasted in the $37-$49 million band.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.
The consensus estimate has shifted -21.15% due to these changes.
VGM Scores
At this time, Myriad has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Following the exact same course, the stock has a grade of C on the value side, putting it in the middle 20% for value investors.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Myriad has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry Player
Myriad is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Moderna (MRNA - Free Report) , a stock from the same industry, has gained 1.6%. The company reported its results for the quarter ended December 2025 more than a month ago.
Moderna reported revenues of $678 million in the last reported quarter, representing a year-over-year change of -29.8%. EPS of -$2.11 for the same period compares with -$2.50 a year ago.
Moderna is expected to post a loss of $2.03 per share for the current quarter, representing a year-over-year change of +19.4%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.2%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Moderna. Also, the stock has a VGM Score of C.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Myriad Genetics (MYGN - Free Report) . Shares have added about 4.1% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Myriad due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Myriad Genetics Tops Q4 Earnings & Revenue Estimates
Myriad Genetics, Inc. reported fourth-quarter 2025 adjusted earnings of 4 cents per share, which surpassed the Zacks Consensus Estimate by 350% and increased 33.3% year over year.
Adjusted earnings exclude amortization expenses from acquired intangible assets, equity compensation and real estate optimization. GAAP loss per share came in at 8 cents in the quarter compared with the prior-year quarter’s loss of 47 cents.
For the full year, adjusted earnings were 6 cents per share compared with the year-ago period’s earnings of 14 cents. The Zacks Consensus Estimate projected the company’s 2025 earnings per share to be flat.
MYGN’s Revenues
Total revenues fell 0.4% year over year to $209.8 million but exceeded the Zacks Consensus Estimate by 1.07%. Testing volumes increased 2% year over year.
For full-year 2025, revenues totaled $824.5 million, declining 1.6% from the year-ago period. The figure topped the Zacks Consensus Estimate slightly by 0.3%.
Detailed Breakdown of MYGN’s Q4 Revenues
In the fourth quarter, Hereditary Cancer testing revenues increased 3% year over year to $96.8 million. Tumor Profiling testing revenues rose 2% year over year to $31.5 million. Prenatal testing revenues came in flat at $44.9 million, while Mental Health revenues decreased 10% to $36.6 million.
MYGN’s Q4 Margin Performance
The gross margin fell 168 basis points (bps) to 70% due to a 5.5% increase in the cost of revenues.
Research and development expenses dropped 14.1% year over year to $25.5 million. SG&A expenses dipped 16.4% to $55.6 million in the reported quarter.
The adjusted operating loss was $3 million compared with a loss of $17.3 million in the year-ago quarter.
MYGN’s Financial Position
Myriad Genetics exited the fourth quarter of 2025 with cash and cash equivalents of $149.6 million compared with $102.4 million at the end of the fourth quarter of 2024.
Long-term debt amounted to $119.9 million, higher than $39.6 million at the end of the fourth quarter of 2024.
The cumulative net cash outflow from operating activities at the end of the reported quarter was $1.8 million compared with an outflow of $8.7 million in the year-ago period.
Myriad Genetics’ 2026 Guidance
Myriad Genetics reiterated its full-year 2026 guidance, which it introduced during preliminary fourth-quarter 2025 results in January. Revenues are expected to be between $860 million and $880 million in 2026. The Zacks Consensus Estimate is pegged at $867.5 million.
Full-year adjusted gross margin is expected to be in the 68%-69% range. Adjusted EBITDA is forecasted in the $37-$49 million band.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.
The consensus estimate has shifted -21.15% due to these changes.
VGM Scores
At this time, Myriad has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Following the exact same course, the stock has a grade of C on the value side, putting it in the middle 20% for value investors.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Myriad has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry Player
Myriad is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Moderna (MRNA - Free Report) , a stock from the same industry, has gained 1.6%. The company reported its results for the quarter ended December 2025 more than a month ago.
Moderna reported revenues of $678 million in the last reported quarter, representing a year-over-year change of -29.8%. EPS of -$2.11 for the same period compares with -$2.50 a year ago.
Moderna is expected to post a loss of $2.03 per share for the current quarter, representing a year-over-year change of +19.4%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.2%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Moderna. Also, the stock has a VGM Score of C.